Payment overview · 2025
General Payments
$353.79
20 reported records · 5 companies
Healthcare provider profile · identity verified
Lance A. Rudolph, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALBUQUERQUE, NM · NPI 1376502997
Verified facts
What the public records show
CMS Open Payments records show Lance A. Rudolph, M.D. received $353.79 in general payments during 2025 across 20 reported records.
Amgen Inc. accounted for 52.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tymlos.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $185.27 | 52.4% | 11 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $63.00 | 17.8% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.84 | 16.9% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.25 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.43 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $353.79 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $185.27 | 11 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $84.00 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $63.00 | 3 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $59.84 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Tymlos tymlos |
2025 | Tymlos | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alendronate Sodium | Alendronate Sodium | 491 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 98 |
| Gabapentin | Gabapentin | 213 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 147 | 39 |
| Lisinopril | Lisinopril | 140 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 30 |
| Losartan Potassium | Losartan Potassium | 117 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 19 |
| Pregabalin | Pregabalin | 76 | 12 |
| Simvastatin | Simvastatin | 75 | 19 |
| Potassium Chloride | Potassium Chloride | 73 | 20 |
| Omeprazole | Omeprazole | 72 | 18 |
| Trazodone Hcl | Trazodone Hcl | 72 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 19 |
| Metformin Hcl Er | Metformin Hcl | 70 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 19 |
| Metformin Hcl | Metformin Hcl | 64 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 18 |
| Spironolactone | Spironolactone | 63 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 16 |
| Furosemide | Furosemide | 59 | 16 |
| Tymlos | Abaloparatide | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 20 |
| Eliquis | Apixaban | 52 | suppressed |
| Allopurinol | Allopurinol | 49 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Lovastatin | Lovastatin | 42 | 11 |
| Sertraline Hcl | Sertraline Hcl | 41 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Alprazolam | Alprazolam | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Acyclovir | Acyclovir | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Meloxicam | Meloxicam | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $353.79 · 20 records | Amgen Inc. | ABRYSVO, COMIRNATY, EVENITY, PREVNAR 20, PROLIA, RECORLEV, STRENSIQ, Tymlos | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tymlos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error